Genetic Technologies Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Kevin Camilleri

Directeur général

AU$296.1k

Rémunération totale

Pourcentage du salaire du PDG	87.0%
Durée du mandat du directeur général	3.3yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	3.3yrs
Durée moyenne du mandat des membres du conseil d'administration	5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Kevin Camilleri a-t-elle évolué par rapport aux bénéfices de Genetic Technologies?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	AU$296k	AU$258k	-AU$12m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$13m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$281k	AU$233k	-AU$12m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$8m
Jun 30 2022	AU$285k	AU$212k	-AU$7m

Rémunération vs marché: La rémunération totale de Kevin ($USD 191.58K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 297.29K ).

Rémunération et revenus: La rémunération de Kevin a augmenté alors que l'entreprise n'est pas rentable.

PDG

Kevin Camilleri (47 yo)

3.3yrs

Titularisation

AU$296,120

Compensation

Mr. Kevin Camilleri serves as Chief Executive Officer of EasyDNA at Genetic Technologies Limited since August 16, 2021. Mr. Camilleri joined the Genetic Technologies Limited in 2021. He has been Chief Oper...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Kevin Camilleri	Chief Executive Officer of EasyDNA	3.3yrs	AU$296.12k	pas de données
Mark Ziirsen	CFO & Company Secretary	less than a year	pas de données	pas de données
Paul Keith Viney	Consultant	5.4yrs	AU$180.45k	pas de données
Erika Spaeth	Director of Clinical & Scientific Affairs	no data	pas de données	pas de données

3.3yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de GTG est considérée comme expérimentée (ancienneté moyenne 3.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Lindsay Wakefield	Independent Non-Executive Director	10.3yrs	AU$74.88k	0.065% A$ 3.7k
Peter Rubinstein	Independent Non-Executive Chairman	6.9yrs	AU$150.19k	2.54% A$ 144.2k
Jerzy Muchnicki	Non-Independent Non-Executive Director	6.9yrs	AU$87.44k	1.55% A$ 87.8k
Finlay Macrae	Member of Scientific & Medical Advisory Board	3.1yrs	pas de données	pas de données
Jon Emery	Member of Scientific & Medical Advisory Board	3.1yrs	pas de données	pas de données
Ora Gordon	Member of Scientific & Medical Advisory Board	3.1yrs	pas de données	pas de données

5.0yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de GTG sont considérés comme expérimentés (ancienneté moyenne 5 ans).

Genetic Technologies Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Independent Non-Executive Chairman recently bought AU$80k worth of stock

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Recent updates

Genetic Technologies Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 0.324648 million.

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide

New major risk - Revenue and earnings growth

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Independent Non-Executive Chairman recently bought AU$80k worth of stock

New major risk - Financial position

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - AU$0.0015 loss per share

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen